Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KMDA 
Kamada (KMDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: KMDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.59% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 395.06M USD | Price to earnings Ratio 21.47 | 1Y Target Price 14 |
Price to earnings Ratio 21.47 | 1Y Target Price 14 | ||
Volume (30-day avg) 3 | Beta 0.06 | 52 Weeks Range 5.27 - 8.90 | Updated Date 10/24/2025 |
52 Weeks Range 5.27 - 8.90 | Updated Date 10/24/2025 | ||
Dividends yield (FY) 3.00% | Basic EPS (TTM) 0.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.22% | Operating Margin (TTM) 15.8% |
Management Effectiveness
Return on Assets (TTM) 4.39% | Return on Equity (TTM) 7.44% |
Valuation
Trailing PE 21.47 | Forward PE 13.46 | Enterprise Value 345921873 | Price to Sales(TTM) 2.33 |
Enterprise Value 345921873 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 2.04 | Enterprise Value to EBITDA 10.11 | Shares Outstanding 57505031 | Shares Floating 9208085 |
Shares Outstanding 57505031 | Shares Floating 9208085 | ||
Percent Insiders 7.2 | Percent Institutions 49.19 |
Upturn AI SWOT
Kamada
Company Overview
History and Background
Kamada Ltd. was founded in 1990 in Israel. It is a plasma-derived protein therapeutics company focusing on specialty plasma-derived products. Initially focused on diagnostic kits, Kamada shifted its focus to therapeutics and has grown through strategic partnerships and product development.
Core Business Areas
- Proprietary Products: Develops, manufactures, and markets specialty plasma-derived products for niche markets. These include GLASSIA (Alpha-1 Antitrypsin [AAT] Deficiency) and CYTOGAM (Cytomegalovirus [CMV] Immunoglobulin Intravenous [Human]).
- Contract Manufacturing: Provides contract manufacturing services to other pharmaceutical companies, leveraging its expertise in protein purification and manufacturing.
Leadership and Structure
Kamada is led by a management team with experience in pharmaceuticals and biotechnology. The company has a board of directors and operates with a functional organizational structure across R&D, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- GLASSIA: GLASSIA is an Alpha-1 Antitrypsin (AAT) therapy used to treat AAT deficiency-related emphysema. Market share is estimated around 25% in the US AAT market. Competitors include CSL Behring (CSL), Takeda (TAK) and Grifols (GRFS). Revenue data is proprietary.
- CYTOGAM: CYTOGAM is a CMV-IGIV (Cytomegalovirus Immune Globulin Intravenous [Human]) used to prevent CMV disease in transplant patients. Market share is relatively smaller and revenue data is proprietary. Competitors are limited as CYTOGAM is a specialized product, but other immunoglobulin therapies exist from companies like Grifols (GRFS) and CSL Behring (CSL).
Market Dynamics
Industry Overview
The plasma-derived therapeutics industry is characterized by high barriers to entry, stringent regulatory requirements, and significant demand for specialized therapies. Growth is driven by aging populations, increased diagnosis rates, and advancements in manufacturing technologies.
Positioning
Kamada occupies a niche position within the plasma-derived therapeutics industry, focusing on specialized products with limited competition and high unmet needs. Its competitive advantages include its expertise in protein purification and its established manufacturing capabilities.
Total Addressable Market (TAM)
The global plasma-derived products market is expected to reach USD 45.91 billion by 2032. Kamada is positioned to grow with this expansion, focusing on niche segments where it has a competitive advantage. The AAT deficiency market represents a portion of this larger TAM.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Established manufacturing capabilities
- Strategic partnerships
- Experienced management team
- Strong brand reputation in niche markets
Weaknesses
- Limited product diversification
- Reliance on a few key products
- Smaller scale compared to major players
- Geographic concentration of revenue
- High R&D costs
Opportunities
- Expanding into new geographic markets
- Developing new plasma-derived therapies
- Acquiring complementary businesses
- Leveraging its manufacturing expertise for contract manufacturing
- Increased awareness of AAT deficiency
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Fluctuations in plasma supply
- Pricing pressures
- Development of alternative therapies
Competitors and Market Share
Key Competitors
- CSL
- TAK
- GRFS
Competitive Landscape
Kamada competes with larger pharmaceutical companies. Its strengths lie in its niche product portfolio and manufacturing expertise, while its weaknesses include its smaller scale and limited product diversification.
Major Acquisitions
Prometic Biotherapeutics Inc's Plasma Resources
- Year: 2017
- Acquisition Price (USD millions): 45
- Strategic Rationale: Acquisition of plasma collection assets aimed to increase raw material supply (plasma) for manufacturing its plasma-derived therapies.
Growth Trajectory and Initiatives
Historical Growth: Kamada has experienced growth through strategic acquisitions, product development, and geographic expansion.
Future Projections: Analyst estimates vary based on market conditions and company performance. Generally, future growth is expected to be driven by increased adoption of its existing products and the development of new therapies.
Recent Initiatives: Recent initiatives include expanding its commercial footprint, investing in R&D, and exploring strategic partnerships.
Summary
Kamada is a niche player in the plasma-derived therapeutics industry. It has a strong position in specialized markets, particularly with GLASSIA. However, the company's reliance on a few key products and smaller scale compared to larger competitors present challenges. Continued product innovation and geographic expansion will be crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data and revenue figures are estimates and may not be precise. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kamada
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-05-31 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 420 | Website https://www.kamada.com |
Full time employees 420 | Website https://www.kamada.com | ||
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.